Regnum (Regnum) Preferred Dividends : $0.00 Mil (TTM As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Regnum Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Regnum's preferred dividends for the three months ended in Mar. 2023 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00 Mil.

Regnum Preferred Dividends Historical Data

The historical data trend for Regnum's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regnum Preferred Dividends Chart

Regnum Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Preferred Dividends

Get a 7-Day Free Trial

Regnum Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Preferred Dividends	Get a 7-Day Free Trial															-	-	-	-	-

Regnum Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Regnum (OTCPK:RGMP) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Regnum (Regnum) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regnum Corp (OTCPK:RGMP) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

N/A

Address

600 Third Avenue, 19th Floor, New York, NY, USA, 10016

Website

https://www.regnumcorp.com

Regnum Corp is focused on developing and commercializing therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a CCR5 antagonist to treat multi-drug resistant HIV infection.

Regnum (Regnum) Headlines

No Headlines